India, July 2 -- The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
Positive clinical updates span across (R/R) diffuse large B-cell lymphoma, Infantile-Onset Pompe disease. The late-stage clinical trial successes and setbacks reflected the sector's ongoing volatility and innovation cycle.
Let us unpack the specifics.
Regulatory Approvals
Novartis Gains EU Nod for Itvisma
Novartis AG (NVS) has received European Commission approval for Itvisma, a gene therapy for patients with 5q spinal muscular atrophy. The one-time intrathecal...